Clinical trials: Vasculitis, Central Nervous System
Giant Cell Arteritis (GCA), Cardiovascular Diseases
TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients
This nationwide observational study emulates a target trial to compare the effect of tocilizumab versus methotrexate initiation on major adverse cardiovascular events (MACE) in patients with incident giant cell arteritis using…
- Trial name
- TACTIC-GCA (NCT07459335)
- Where
- 2 sites in France
- Volunteers
- 1,667 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to…
- Trial name
- NCT04474847
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis (GCA)
Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
Giant cell arteritis is a vasculitis, i.e. inflammation of the artery walls, which generally affects people over the age of 50. Diagnosis can be long and difficult, as the clinical signs are not specific (headache, pain in the…
- Trial name
- QuickDx-GCA (NCT06742671)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
- Trial name
- NCT03923738
- Testing
- Tocilizumab
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis, Vasculitis
FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis
Giant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment.
- Trial name
- NCT05000138
- Testing
- FDG PET/CT
- Where
- 5 sites in Canada, France and 1 more
- Volunteers
- 92 people
- Sponsor
- Jewish General Hospital
Giant Cell Arteritis
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose until 0.1 mg/Kg/d or less after 6 months of treatment.
- Trial name
- HORTOCI (NCT01910038)
- Testing
- corticoids+ tocilizumab 8mg/Kg/4 weeks
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis, Large Vessel Giant Cell Arteriitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Longitudinal imaging in patients with large vessel vasculitis to predict further disease course
- Trial name
- NCT04204876
- Testing
- Magnet Resonance Imaging (MRI), PET/CT analysis
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
MPO-ANCA Vasculitis, Microscopic Polyangiitis
CellCept in p-ANCA Vasculitis
Microscopic polyangiitis (MP) is a primary systemic vasculitis predominantly affecting small blood vessels. Following the widespread introduction of ANCA testing, the primary systemic vasculitis (SV), Wegener?s granulomatosis…
- Trial name
- NCT00405860
- Testing
- CellCept (mycophenolate mofetil)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Autoimmune Diseases, Non-small Cell Lung Cancer
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis
- Trial name
- NCT03656627
- Testing
- Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Giant Cell Arteritis
Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis
The factors underlying the large interindividual variability in response to glucocorticoids in Giant Cell Arteritis are poorly understood.
- Trial name
- PREDICORT (NCT01400464)
- Testing
- Prednisone therapy and pharmacokinetic
- Where
- 12 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
The purpose of this study is to observe the clinical manifestation, Lab findings including chest CT scans, pathological findings and outcomes in chinese patients with pulminary vasculitis.
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, EosinphilicGranulomatosis With Polyangiitis
- Trial name
- NCT02126098
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Wegener Granulomatosis, Microscopic Polyangiitis
Vasculitis Illness Perception (VIP) Study
The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa
- Trial name
- NCT02190916
- Where
- United States
- Volunteers
- 707 people
- Sponsor
- University of South Florida
Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
The purpose of this study is to determine the safety and efficacy of a therapeutic regimen consisting of 4 weeks of glucocorticoids given with a combination of the usual induction agents for ANCA-associated vasculitis.
- Trial name
- SAFE-LOW (NCT06983821)
- Testing
- Cyclophosphamide, Standard of Care (SOC), Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Hospital Research Institute
Giant Cell Arteritis
TocilizuMab discontinuAtion in GIant Cell Arteritis
Giant cell arteritis (GCA) is a large-vessel vasculitis that typically occurs in people over the age of 50. Corticosteroids (GC) are the cornerstone of treatment for GCA.
- Trial name
- MAGICA (NCT06037460)
- Testing
- Tocilizumab treatment, questionnaires, Blood samples
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment
Giant cell arteritis (GCA) affects large and medium sized vessels. Large vessel-GCA (LV-GCA) affecting aorta and/or its main branches is seen a) together with temporal arteritis (AT-GCA), b) as isolated LV-GCA but also c) with…
- Trial name
- NCT03285945
- Testing
- PET3, PET10
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg bodyweight i.v.
- Trial name
- GUSTO (NCT03745586)
- Testing
- Tocilizumab, Glucocorticoids
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern